NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $117.58
  • Forecasted Upside: 42.55 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$82.48
▲ +0.41 (0.50%)
1 month | 3 months | 12 months
Get New BioMarin Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$117.58
▲ +42.55% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $117.58, with a high forecast of $218.00 and a low forecast of $82.00. The average price target represents a 42.55% upside from the last price of $82.48.

Buy

The current consensus among 16 contributing investment analysts is to buy stock in BioMarin Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 10 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 10 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2021WedbushReiterated RatingBuy$139.00Low
i
Rating by Liana Moussatos at Wedbush
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$102.00Medium
i
4/19/2021Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $82.00Low
i
3/23/2021WedbushReiterated RatingOutperform$139.00Medium
i
3/1/2021Canaccord GenuityLower Price TargetBuy$95.00 ➝ $91.00Low
i
3/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$90.00 ➝ $100.00Low
i
3/1/2021Robert W. BairdReiterated RatingBuyLow
i
1/11/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$100.00 ➝ $110.00High
i
11/6/2020SVB LeerinkLower Price TargetOutperform$113.00 ➝ $108.00High
i
9/10/2020TruistLower Price Target$130.00 ➝ $125.00Low
i
9/10/2020WedbushReiterated RatingBuyHigh
i
Rating by Liana Moussatos at Wedbush
8/21/2020Morgan StanleyLower Price TargetEqual Weight$125.00 ➝ $85.00Low
i
8/20/2020TruistLower Price Target$143.00 ➝ $130.00Low
i
8/20/2020OppenheimerLower Price Target$116.00 ➝ $88.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/20/2020Canaccord GenuityLower Price TargetBuy$119.00 ➝ $95.00Low
i
8/20/2020Jefferies Financial GroupLower Price TargetBuy$138.00 ➝ $118.00Medium
i
8/20/2020William BlairReiterated RatingOutperform ➝ Market PerformMedium
i
Rating by T. Lugo at William Blair
8/19/2020CitigroupDowngradeBuy ➝ Neutral$148.00 ➝ $86.00Medium
i
8/19/2020WedbushReiterated RatingBuy$136.00Medium
i
Rating by Liana Moussatos at Wedbush
8/19/2020SVB LeerinkLower Price TargetOutperform$140.00 ➝ $113.00High
i
8/19/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$123.00 ➝ $92.00High
i
8/19/2020Stifel NicolausDowngradeBuy ➝ Hold$127.00 ➝ $100.00High
i
8/14/2020The Goldman Sachs GroupBoost Price Target$172.00 ➝ $218.00Low
i
8/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$94.00 ➝ $108.00Low
i
8/5/2020OppenheimerInitiated CoverageHold$116.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/5/2020WedbushReiterated RatingBuy$146.00Low
i
Rating by Liana Moussatos at Wedbush
8/5/2020BarclaysBoost Price Target$125.00 ➝ $135.00Low
i
8/5/2020Piper SandlerBoost Price Target$120.00 ➝ $133.00Low
i
8/5/2020Credit Suisse GroupReiterated RatingBuy$128.00Medium
i
8/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $156.00Low
i
8/5/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $140.00Low
i
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$140.00Low
i
7/27/2020WedbushReiterated RatingBuy$145.00Low
i
Rating by Liana Moussatos at Wedbush
7/24/2020Robert W. BairdBoost Price Target$125.00 ➝ $140.00Low
i
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$125.00Low
i
7/6/2020CitigroupBoost Price TargetBuy$105.00 ➝ $148.00Low
i
6/21/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
6/18/2020WedbushReiterated RatingBuy$145.00High
i
Rating by Liana Moussatos at Wedbush
6/18/2020SunTrust BanksBoost Price Target$109.00 ➝ $143.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
6/18/2020OppenheimerBoost Price TargetPerformer$88.00 ➝ $95.00High
i
6/17/2020SunTrust BanksBoost Price TargetBuy$109.00 ➝ $143.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
6/10/2020Bank of AmericaBoost Price TargetBuy$120.00 ➝ $130.00Low
i
6/5/2020BarclaysBoost Price Target$105.00 ➝ $125.00Medium
i
6/3/2020WedbushReiterated RatingBuy$145.00Medium
i
Rating by Liana Moussatos at Wedbush
6/1/2020Credit Suisse GroupReiterated RatingBuy$128.00Low
i
5/10/2020CfraReiterated RatingBuy$115.00Low
i
5/8/2020Canaccord GenuityBoost Price Target$108.00 ➝ $119.00Low
i
5/7/2020Credit Suisse GroupReiterated RatingBuy$128.00High
i
5/1/2020WedbushReiterated RatingOutperform$145.00Low
i
Rating by Liana Moussatos at Wedbush
5/1/2020William BlairReiterated RatingBuyLow
i
5/1/2020Canaccord GenuityReiterated RatingBuy$108.00High
i
4/30/2020SunTrust BanksLower Price TargetBuy$110.00 ➝ $109.00High
i
4/30/2020NomuraReiterated RatingHold$77.00High
i
4/30/2020Credit Suisse GroupLower Price TargetOutperform$131.00 ➝ $128.00High
i
4/30/2020OppenheimerReiterated RatingHold$88.00High
i
4/6/2020WedbushReiterated RatingBuy$164.00High
i
Rating by Liana Moussatos at Wedbush
3/24/2020WedbushReiterated RatingOutperformHigh
i
Rating by Liana Moussatos at Wedbush
3/3/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $125.00Low
i
3/2/2020Nomura SecuritiesReiterated RatingHold$77.00Medium
i
Rating by Christopher Marai at Nomura Securities
3/1/2020WedbushReiterated RatingBuy$164.00High
i
Rating by Liana Moussatos at Wedbush
2/28/2020CitigroupBoost Price Target$95.00 ➝ $105.00Medium
i
2/28/2020BarclaysReiterated RatingBuy$100.00Medium
i
Rating by Gena Wang at Barclays PLC
2/27/2020OppenheimerBoost Price Target$88.00 ➝ $80.00Medium
i
2/23/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
2/21/2020WedbushReiterated RatingOutperform$158.00 ➝ $175.00Low
i
Rating by Liana Moussatos at Wedbush
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$94.00Medium
i
1/24/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$111.00 ➝ $113.00Low
i
Rating by Kennen MacKay at Royal Bank of Canada
1/21/2020WedbushReiterated RatingBuy$158.00Low
i
Rating by Liana Moussatos at Wedbush
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
12/23/2019WedbushReiterated RatingBuy$158.00N/A
i
Rating by Liana Moussatos at Wedbush
12/17/2019WedbushReiterated RatingBuy$158.00Low
i
Rating by Liana Moussatos at Wedbush
12/16/2019Cantor FitzgeraldReiterated RatingBuy$129.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
12/16/2019Royal Bank of CanadaReiterated RatingHold$111.00Low
i
Rating by Kennen MacKay at Royal Bank of Canada
12/16/2019CowenReiterated RatingBuy$150.00Medium
i
12/13/2019Robert W. BairdReiterated RatingBuy$120.00High
i
Rating by Michael Ulz at Robert W. Baird
12/11/2019Bank of AmericaReiterated RatingBuy$90.00High
i
11/27/2019BarclaysUpgradeEqual Weight ➝ Overweight$86.00 ➝ $98.00Medium
i
11/22/2019WedbushReiterated RatingBuy$157.00Low
i
Rating by Liana Moussatos at Wedbush
11/15/2019William BlairReiterated RatingBuyLow
i
11/12/2019SunTrust BanksInitiated CoverageBuy$110.00Medium
i
10/30/2019CitigroupReiterated RatingBuy$120.00 ➝ $95.00Low
i
10/28/2019Canaccord GenuityLower Price TargetBuy$117.00 ➝ $108.00Low
i
10/25/2019WedbushBoost Price TargetOutperform$128.00 ➝ $152.00Low
i
Rating by Liana Moussatos at Wedbush
10/24/2019Nomura SecuritiesLower Price Target$93.00 ➝ $77.00Medium
i
10/24/2019BarclaysLower Price TargetEqual Weight$95.00 ➝ $86.00Medium
i
10/21/2019Cantor FitzgeraldSet Price TargetBuy$129.00High
i
Rating by Eliana Merle at Cantor Fitzgerald
10/16/2019Bank of AmericaInitiated CoverageBuy$90.00Low
i
9/26/2019WedbushSet Price TargetBuy$128.00High
i
Rating by Liana Moussatos at Wedbush
9/13/2019Piper Jaffray CompaniesSet Price TargetBuy$120.00Medium
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/13/2019Stifel NicolausSet Price TargetBuy$108.00Medium
i
Rating by Paul Matteis at Stifel Nicolaus
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$133.00High
i
7/10/2019WedbushReiterated RatingOutperform$128.00Medium
i
Rating by Liana Moussatos at Wedbush
6/19/2019WedbushReiterated RatingOutperform$128.00Low
i
Rating by Liana Moussatos at Wedbush
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
5/28/2019WedbushReiterated RatingBuy$128.00Medium
i
Rating by Liana Moussatos at Wedbush
5/23/2019CitigroupReiterated RatingBuy ➝ BuyLow
i
4/26/2019Robert W. BairdSet Price TargetBuy$120.00Low
i
Rating by Michael Ulz at Robert W. Baird
4/26/2019WedbushBoost Price TargetOutperform ➝ Outperform$127.00 ➝ $128.00Low
i
Rating by Liana Moussatos at Wedbush
4/26/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
4/9/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$110.00Low
i
Rating by Laura Chico at Raymond James
4/2/2019Robert W. BairdSet Price TargetBuy$120.00Low
i
Rating by Michael Ulz at Robert W. Baird
4/2/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
3/4/2019Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$131.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
2/26/2019WedbushSet Price TargetBuy$127.00Low
i
Rating by Liana Moussatos at Wedbush
2/25/2019SunTrust BanksLower Price TargetBuy$117.00Medium
i
2/24/2019BarclaysReiterated RatingHold$95.00High
i
2/22/2019OppenheimerLower Price Target$92.00 ➝ $81.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
2/7/2019WedbushReiterated RatingOutperform$127.00Low
i
Rating by Liana Moussatos at Wedbush
1/8/2019OppenheimerSet Price TargetHold$92.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
1/7/2019CowenReiterated RatingBuyMedium
i
1/7/2019Cantor FitzgeraldReiterated RatingBuy$126.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$83.16Medium
i
Rating by Laura Chico at Raymond James
12/17/2018GuggenheimInitiated CoverageNeutralHigh
i
Rating by Whitney Ijem at Guggenheim
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
i
12/13/2018OppenheimerInitiated CoverageHold$92.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
11/28/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
11/14/2018WedbushSet Price TargetBuy$127.00Low
i
Rating by Liana Moussatos at Wedbush
11/4/2018Cantor FitzgeraldReiterated RatingBuy$126.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
10/29/2018WedbushSet Price TargetBuy$127.00Medium
i
Rating by Liana Moussatos at Wedbush
10/26/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$113.00 ➝ $114.00Low
i
10/26/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
10/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$113.00 ➝ $116.00Low
i
10/16/2018Jefferies Financial GroupBoost Price TargetFair Value ➝ Buy$125.00High
i
10/15/2018Cantor FitzgeraldSet Price TargetBuy$126.00High
i
Rating by Eliana Merle at Cantor Fitzgerald
10/7/2018Cantor FitzgeraldSet Price TargetBuy$126.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
9/28/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$126.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
9/13/2018WedbushSet Price TargetBuy$120.00Low
i
Rating by Liana Moussatos at Wedbush
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$108.00 ➝ $120.00Low
i
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$115.00 ➝ $120.00High
i
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$135.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/5/2018BarclaysReiterated RatingEqual Weight ➝ Hold$95.00 ➝ $98.00High
i
8/3/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$113.00 ➝ $115.00High
i
8/3/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$102.00 ➝ $109.00High
i
7/31/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$105.00 ➝ $113.00Medium
i
7/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$120.00 ➝ $122.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
6/20/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/31/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$127.00 ➝ $133.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/29/2018CitigroupBoost Price TargetBuy$108.00Low
i
5/25/2018WedbushBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $115.00Low
i
Rating by L. Moussatos at Wedbush
5/25/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$116.00 ➝ $120.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/25/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$101.00 ➝ $105.00High
i
5/16/2018Canaccord GenuityInitiated CoverageBuy$101.00Low
i
5/15/2018WedbushReiterated RatingOutperform$112.00Low
i
Rating by L. Moussatos at Wedbush
5/7/2018SVB LeerinkBoost Price TargetOutperform$132.00 ➝ $145.00Medium
i
4/30/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$112.00 ➝ $113.00High
i
4/30/2018WedbushLower Price TargetOutperform$112.00 ➝ $110.00Medium
i
Rating by L. Moussatos at Wedbush
4/30/2018Sanford C. BernsteinLower Price TargetMarket Perform$97.00 ➝ $92.00Medium
i
4/26/2018JPMorgan Chase & Co.Set Price TargetBuy$127.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/29/2018Credit Suisse GroupReiterated RatingBuy$116.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
3/12/2018WedbushReiterated RatingOutperform$110.00Medium
i
Rating by L. Moussatos at Wedbush
3/2/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$113.00 ➝ $116.00High
i
Rating by Alethia Young at Credit Suisse Group AG
2/27/2018Royal Bank of CanadaReiterated RatingHold$94.00Medium
i
2/25/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/25/2018Credit Suisse GroupReiterated RatingBuy$113.00Low
i
2/23/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$115.00 ➝ $112.00Medium
i
2/23/2018Stifel NicolausLower Price TargetBuy ➝ Buy$105.00 ➝ $102.00High
i
2/23/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$142.00 ➝ $132.00High
i
2/23/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$119.00 ➝ $125.00High
i
2/23/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$119.00 ➝ $124.00High
i
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Outperform$131.00 ➝ $129.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$114.00Low
i
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$113.00Low
i
12/22/2017WedbushReiterated RatingOutperform$110.00Medium
i
Rating by L. Moussatos at Wedbush
12/15/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
i
12/14/2017WedbushUpgradeNeutral ➝ Outperform$110.00Low
i
Rating by L. Moussatos at Wedbush
12/11/2017SunTrust BanksBoost Price TargetBuy$130.00High
i
Rating by Edward Nash at SunTrust Banks, Inc.
11/27/2017JPMorgan Chase & Co.Set Price TargetBuy$131.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/15/2017WedbushReiterated RatingNeutral$108.00N/A
i
10/29/2017JPMorgan Chase & Co.Set Price TargetBuy$130.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$117.00 ➝ $119.00N/A
i
10/27/2017Stifel NicolausLower Price TargetBuy$107.00 ➝ $105.00N/A
i
10/20/2017BMO Capital MarketsReiterated RatingBuy$117.00N/A
i
10/19/2017SunTrust BanksSet Price TargetBuy$115.00N/A
i
Rating by Edward Nash at SunTrust Banks, Inc.
10/19/2017SVB LeerinkReiterated RatingOutperform$136.00 ➝ $142.00N/A
i
Rating by Dae Gon Ha at SVB Leerink LLC
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 ➝ $124.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$129.00N/A
i
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 ➝ $117.00N/A
i
9/26/2017Jefferies Financial GroupReiterated RatingBuy$116.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/21/2017Piper Jaffray CompaniesReiterated RatingBuy$113.00Medium
i
9/15/2017BMO Capital MarketsReiterated RatingBuyLow
i
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$93.00Medium
i
9/14/2017Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Overweight$113.00Medium
i
8/31/2017CitigroupInitiated CoverageBuy ➝ Buy$98.00Medium
i
8/25/2017Jefferies Financial GroupSet Price TargetBuy$116.00Low
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$100.00High
i
8/9/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$118.00 ➝ $119.00Low
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
8/7/2017WedbushReiterated RatingNeutral$108.00High
i
8/4/2017Stifel NicolausReiterated RatingBuy$107.00Low
i
8/4/2017CowenReiterated RatingBuyLow
i
8/3/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$118.00 ➝ $119.00Low
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
8/3/2017UBS GroupReiterated RatingNeutral$92.00 ➝ $93.00Low
i
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00High
i
7/22/2017BarclaysReiterated RatingEqual Weight$105.00 ➝ $100.00Low
i
7/18/2017SVB LeerinkReiterated RatingBuyLow
i
Rating by Dae Gon Ha at SVB Leerink LLC
7/14/2017SunTrust BanksReiterated RatingBuy$115.00Low
i
7/13/2017BMO Capital MarketsReiterated RatingOutperform$111.00 ➝ $115.00Medium
i
7/11/2017CowenReiterated RatingBuyMedium
i
5/15/2017Jefferies Financial GroupReiterated RatingBuy$116.00N/A
i
5/15/2017CowenReiterated RatingBuy$150.00N/A
i
Rating by Phil Nadeau at Cowen Inc
5/8/2017WedbushReiterated RatingHold$108.00Low
i
5/5/2017CowenReiterated RatingBuy$150.00Low
i
Rating by Phil Nadeau at Cowen Inc
5/5/2017Jefferies Financial GroupReiterated RatingBuy$116.00High
i
5/1/2017JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/28/2017Credit Suisse GroupReiterated RatingBuy$116.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/28/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$103.00 ➝ $105.00Low
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
4/26/2017Jefferies Financial GroupReiterated RatingBuy$116.00Medium
i
4/24/2017CowenReiterated RatingBuy$150.00Low
i
Rating by Phil Nadeau at Cowen Inc
4/24/2017BMO Capital MarketsLower Price TargetOutperform$112.00 ➝ $105.00Low
i
4/18/2017Credit Suisse GroupReiterated RatingOutperform$112.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/18/2017CowenReiterated RatingOutperform$150.00Low
i
Rating by Phil Nadeau at Cowen Inc
3/29/2017UBS GroupInitiated CoverageNeutral ➝ Neutral$92.00N/A
i
3/15/2017CowenReiterated RatingOutperform$150.00Low
i
Rating by Phil Nadeau at Cowen Inc
3/8/2017CowenReiterated RatingOutperform$150.00Low
i
Rating by Phil Nadeau at Cowen Inc
3/1/2017Nomura InstinetInitiated CoverageNeutral ➝ Neutral$93.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageNeutralN/A
i
2/27/2017WedbushReiterated RatingNeutral$102.00N/A
i
2/25/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/24/2017CowenReiterated RatingBuy$150.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/10/2017GabelliReiterated RatingBuyN/A
i
Rating by Jing He at Gabelli
2/8/2017WedbushReiterated RatingNeutral$102.00N/A
i
2/7/2017Morgan StanleyInitiated CoverageOverweight$110.00N/A
i
1/23/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$111.00 ➝ $107.00N/A
i
Rating by alethia young at Credit Suisse Group AG
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/A
i
Rating by Brian Skorney at Robert W. Baird
12/25/2016GabelliInitiated CoverageBuyN/A
i
Rating by Jing He at Gabelli
12/9/2016CowenSet Price TargetBuy$150.00N/A
i
Rating by Phil Nadeau at Cowen Inc
12/8/2016GabelliInitiated CoverageBuy$109.00N/A
i
Rating by J. He at Gabelli
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$125.00 ➝ $105.00N/A
i
Rating by Geoff Meacham at Barclays PLC
11/7/2016Credit Suisse GroupReiterated RatingBuy$111.00N/A
i
Rating by alethia young at Credit Suisse Group AG
11/7/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$105.00 ➝ $84.00N/A
i
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$106.00N/A
i
10/31/2016JPMorgan Chase & Co.Reiterated RatingBuy$127.00N/A
i
Rating by cory kasimov at JPMorgan Chase & Co.
10/30/2016Royal Bank of CanadaSet Price TargetBuy$125.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
10/28/2016WedbushReiterated RatingNeutral$102.00 ➝ $104.00N/A
i
10/15/2016Robert W. BairdSet Price TargetBuy$115.00N/A
i
Rating by Michael Ulz at Robert W. Baird
10/14/2016Robert W. BairdReiterated RatingPositive$115.00N/A
i
10/13/2016SVB LeerinkReiterated RatingOutperform$127.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
10/7/2016The Goldman Sachs GroupUpgradeNeutralN/A
i
9/16/2016SVB LeerinkReiterated RatingOutperform$127.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
9/8/2016CowenSet Price TargetBuy$150.00N/A
i
Rating by phil nadeau at Cowen Inc
9/7/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by cory kasimov at JPMorgan Chase & Co.
9/6/2016WedbushReiterated RatingNeutral$108.00 ➝ $104.00N/A
i
Rating by Liana Moussatos at Wedbush
8/19/2016Piper Jaffray CompaniesReiterated RatingOverweightN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/17/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
8/8/2016Credit Suisse GroupSet Price TargetBuy$111.00N/A
i
Rating by alethia young at Credit Suisse Group AG
8/5/2016JPMorgan Chase & Co.Boost Price TargetOverweight$120.00 ➝ $127.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/5/2016Jefferies Financial GroupBoost Price TargetBuy$116.00 ➝ $120.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
8/5/2016Piper Jaffray CompaniesBoost Price TargetOverweight$107.00 ➝ $120.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 ➝ $113.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
8/5/2016BarclaysBoost Price TargetOverweight$105.00 ➝ $125.00N/A
i
Rating by Geoff Meacham at Barclays PLC
7/28/2016William BlairSet Price TargetBuy$116.00N/A
i
Rating by Tim Lugo at William Blair
7/28/2016Jefferies Financial GroupSet Price TargetBuy$116.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
7/28/2016Credit Suisse GroupSet Price TargetBuy$111.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
7/28/2016WedbushReiterated RatingNeutral$108.00N/A
i
Rating by Liana Moussatos at Wedbush
7/28/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
7/28/2016SVB LeerinkReiterated RatingOutperform$107.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
7/28/2016Robert W. BairdBoost Price TargetOutperform$110.00 ➝ $115.00N/A
i
Rating by Brian Skorney at Robert W. Baird
6/22/2016SVB LeerinkReiterated RatingOutperform$107.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/20/2016OppenheimerReiterated RatingMarket Perform$99.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/16/2016BarclaysReiterated RatingBuyN/A
i
Rating by Geoff Meacham at Barclays PLC
(Data available from 6/14/2016 forward)
BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $82.48
$82.17
$83.45

50 Day Range

MA: $78.42
$75.51
$83.67

52 Week Range

Now: $82.48
$71.35
$131.95

Volume

632,335 shs

Average Volume

1,124,377 shs

Market Capitalization

$15.07 billion

P/E Ratio

20.32

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?

The following equities research analysts have issued research reports on BioMarin Pharmaceutical in the last twelve months: Barclays PLC, BMO Capital Markets, Canaccord Genuity, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BMRN.

What is the current price target for BioMarin Pharmaceutical?

19 Wall Street analysts have set twelve-month price targets for BioMarin Pharmaceutical in the last year. Their average twelve-month price target is $117.58, suggesting a possible upside of 43.3%. The Goldman Sachs Group, Inc. has the highest price target set, predicting BMRN will reach $218.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $82.00 for BioMarin Pharmaceutical in the next year.
View the latest price targets for BMRN.

What is the current consensus analyst rating for BioMarin Pharmaceutical?

BioMarin Pharmaceutical currently has 7 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMRN will outperform the market and that investors should add to their positions of BioMarin Pharmaceutical.
View the latest ratings for BMRN.

What other companies compete with BioMarin Pharmaceutical?

How do I contact BioMarin Pharmaceutical's investor relations team?

BioMarin Pharmaceutical's physical mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company's listed phone number is 415-506-6700 and its investor relations email address is [email protected] The official website for BioMarin Pharmaceutical is www.bmrn.com.